惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

Google DeepMind News
Google DeepMind News
WordPress大学
WordPress大学
S
SegmentFault 最新的问题
小众软件
小众软件
爱范儿
爱范儿
freeCodeCamp Programming Tutorials: Python, JavaScript, Git & More
量子位
博客园_首页
T
Tailwind CSS Blog
The Cloudflare Blog
J
Java Code Geeks
奇客Solidot–传递最新科技情报
奇客Solidot–传递最新科技情报
U
Unit 42
OSCHINA 社区最新新闻
OSCHINA 社区最新新闻
人人都是产品经理
人人都是产品经理
N
Netflix TechBlog - Medium
Cyber Security Advisories - MS-ISAC
Cyber Security Advisories - MS-ISAC
腾讯CDC
P
Proofpoint News Feed
aimingoo的专栏
aimingoo的专栏
Recent Announcements
Recent Announcements
T
The Blog of Author Tim Ferriss
D
Docker
Microsoft Azure Blog
Microsoft Azure Blog

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Cabaletta Bio Q1 Earnings: More Positive Data Suggests CA...
2026-05-14 · via All Articles on Seeking Alpha

Summary

  • Cabaletta Bio, Inc. is reaffirmed as a Buy despite recent share price volatility, driven by tangible clinical and manufacturing progress.
  • Key catalysts include registrational trials for rese-cel in myositis, promising early data in myasthenia gravis and pemphigus vulgaris, and upcoming SLE and SSc readouts.
  • Rese-cel’s outpatient-friendly safety profile, removal of preconditioning, and scalable manufacturing platform position CABA for significant autoimmune market opportunities.
  • CABA risks remain high due to limited cash runway, potential dilution, and the need for durable, long-term efficacy data to support commercial viability.
  • This idea was discussed in more depth with members of my private investing community, Haggerston BioHealth. Learn More »
Young female scientist working in laboratory

Solskin/DigitalVision via Getty Images

Investment Overview - Preview To Today's Earnings News

I have issued Cabaletta Bio, Inc. (CABA) stock with Buy ratings in two previous notes for Seeking Alpha, the first in September 2023, with stock

14.92K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in CABA over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.